银华中证创新药产业ETF发起式联接C(012782)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-3,381,178.85 |
-6,474,405.33 |
-3,431,286.58 |
-410,570.78 |
| 本期利润 |
19,422,052.39 |
-14,426,136.22 |
-20,697,634.88 |
-6,056,756.88 |
| 加权平均基金份额本期利润 |
0.07 |
-0.11 |
-0.18 |
-0.10 |
| 本期加权平均净值利润率(%) |
11.95 |
-19.85 |
-30.96 |
-14.09 |
| 本期基金份额净值增长率(%) |
13.08 |
-14.22 |
-24.37 |
-11.68 |
| 期末可供分配利润 |
-74,298,192.89 |
-134,757,106.54 |
-70,105,113.84 |
-37,694,424.25 |
| 期末可供分配基金份额利润 |
-0.35 |
-0.42 |
-0.49 |
-0.33 |
| 期末基金资产净值 |
140,620,821.55 |
185,021,399.56 |
73,002,864.86 |
78,097,224.22 |
| 期末基金份额净值 |
0.65 |
0.58 |
0.51 |
0.67 |
| 基金份额累计净值增长率(%) |
-34.57 |
-42.14 |
-48.99 |
-32.55 |
微信公众号
证券之星APP
基本资料
